Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024

被引：0

作者：

Link-Gelles, Ruth ^{[1
]}

Rowley, Elizabeth A. K. ^{[2
]}

DeSilva, Malini B. ^{[3
]}

Dascomb, Kristin ^{[4
]}

Irving, Stephanie A. ^{[5
]}

Klein, Nicola P. ^{[6
]}

Grannis, Shaun J. ^{[7
,8
]}

Ong, Toan C. ^{[9
]}

Weber, Zachary A. ^{[2
]}

Fleming-Dutra, Katherine E. ^{[1
]}

McEvoy, Charlene E. ^{[3
]}

Akinsete, Omobosola ^{[3
]}

Bride, Daniel ^{[10
]}

Sheffield, Tamara ^{[11
]}

Naleway, Allison L. ^{[5
]}

Zerbo, Ousseny ^{[6
]}

Fireman, Bruce ^{[6
]}

Hansen, John ^{[6
]}

Goddard, Kristin ^{[6
]}

Dixon, Brian E. ^{[7
,12
]}

Rogerson, Colin ^{[7
,13
]}

Fadel, William F. ^{[7
,14
]}

Duszynski, Thomas ^{[7
,15
]}

Rao, Suchitra ^{[9
]}

Barron, Michelle A. ^{[9
]}

Reese, Sarah E. ^{[2
]}

Ball, Sarah W. ^{[2
]}

Dunne, Margaret M. ^{[2
]}

Natarajan, Karthik ^{[16
]}

Okwuazi, Erica ^{[17
]}

Shah, Ami B. ^{[17
]}

Wiegand, Ryan ^{[1
]}

Tenforde, Mark W. ^{[18
]}

Payne, Amanda B. ^{[1
]}

机构：

[1] Natl Ctr Immunizat & Resp Dis, Coronavirus & Other Resp Viruses Div, CDC, Atlanta, GA 30333 USA

[2] Westat Corp, Rockville, MD USA

[3] HealthPartners Inst, Minneapolis, MN USA

[4] Intermt Healthcare, Div Infect Dis & Clin Epidemiol, Salt Lake City, UT USA

[5] Kaiser Permanente Ctr Hlth Res, Portland, OR USA

[6] Kaiser Permanente Northern Calif, Oakland, CA USA

[7] Ctr Biomed Informat, Regenstrief Inst, Indianapolis, IN USA

[8] Indiana Univ, Sch Med, Dept Family Med, Indianapolis, IN USA

[9] Univ Colorado, Anschutz Med Campus, Aurora, CO USA

[10] Intermt Hlth, Enterprise Analyt, Salt Lake City, UT USA

[11] Immunizat Programs, Intermt Hlth, Salt Lake City, UT USA

[12] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Dept Hlth Policy & Management, Indianapolis, IN USA

[13] Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN USA

[14] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Dept Biostat & Hlth Data Sci, Indianapolis, IN USA

[15] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Dept Epidemiol, Indianapolis, IN USA

[16] Columbia Univ, Irving Med Ctr, Dept Biomed Informat, New York, NY USA

[17] Gen Dynam Informat Technol, Falls Church, VA USA

[18] CDC, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA USA

来源：

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT | 2024年 / 73卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged >= 6 months to prevent COVID-19, including severe disease. As with past COVID-19 vaccines, additional doses may be considered for persons with immunocompromising conditions, who are at higher risk for severe COVID-19 and might have decreased response to vaccination. In this analysis, vaccine effectiveness (VE) of an updated COVID-19 vaccine dose against COVID-19-associated hospitalization was evaluated during September 2023-February 2024 using data from the VISION VE network. Among adults aged >= 18 years with immunocompromising conditions, VE against COVID-19- associated hospitalization was 38% in the 7-59 days after receipt of an updated vaccine dose and 34% in the 60-119 days after receipt of an updated dose. Few persons (18%) in this high -risk study population had received updated COVID-19 vaccine. All persons aged >= 6 months should receive updated 2023-2024 COVID-19 vaccination; persons with immunocompromising conditions may get additional updated COVID-19 vaccine doses >= 2 months after the last recommended COVID-19 vaccine.

引用

页码：271 / 276

页数：6

共 34 条

[1] Interim effectiveness of the updated 2023-2024 COVID-19 vaccines in adults with immunocompromizing conditions
Pereira, Marcus R.
AMERICAN JOURNAL OF TRANSPLANTATION, 2024, 24 (06) : 890 - 891
[2] Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, 18 October 2023-9 March 2024
Ma, Kevin C.
Surie, Diya
Lauring, Adam S.
Martin, Emily T.
Leis, Aleda M.
Papalambros, Leigh
Gaglani, Manjusha
Columbus, Christie
Gottlieb, Robert L.
Ghamande, Shekhar
Peltan, Ithan D.
Brown, Samuel M.
Ginde, Adit A.
Mohr, Nicholas M.
Gibbs, Kevin W.
Hager, David N.
Saeed, Safa
Prekker, Matthew E.
Gong, Michelle Ng
Mohamed, Amira
Johnson, Nicholas J.
Srinivasan, Vasisht
Steingrub, Jay S.
Khan, Akram
Hough, Catherine L.
Duggal, Abhijit
Wilson, Jennifer G.
Qadir, Nida
Chang, Steven Y.
Mallow, Christopher
Kwon, Jennie H.
Parikh, Bijal
Exline, Matthew C.
Vaughn, Ivana A.
Ramesh, Mayur
Safdar, Basmah
Mosier, Jarrod
Harris, Estelle S.
Shapiro, Nathan, I
Felzer, Jamie
Zhu, Yuwei
Grijalva, Carlos G.
Halasa, Natasha
Chappell, James D.
Womack, Kelsey N.
Rhoads, Jillian P.
Baughman, Adrienne
Swan, Sydney A.
Johnson, Cassandra A.
Rice, Todd W.
CLINICAL INFECTIOUS DISEASES, 2024,
[3] Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024
Link-Gelles, Ruth
Ciesla, Allison Avrich
Mak, Josephine
Miller, Joseph D.
Silk, Benjamin J.
Lambrou, Anastasia S.
Paden, Clinton R.
Shirk, Philip
Britton, Amadea
Smith, Zachary R.
Fleming-Dutra, Katherine E.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2024, 73 (04): : 77 - 83
[4] Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024
Antunes, Liliana
Mazagatos, Clara
Martinez-Baz, Ivan
Naesens, Reinout
Borg, Maria-Louise
Petrovic, Goranka
Fatukasi, Terra
Jancoriene, Ligita
Machado, Ausenda
Oroszi, Beatrix
Husa, Petr
Lazar, Mihaela
Duerrwald, Ralf
Howard, Jennifer
Melo, Aryse
Perez-Gimeno, Gloria
Castilla, Jesus
Bernaert, Eva
Dziugyte, Ausra
Makaric, Zvjezdana Lovric
Fitzgerald, Margaret
Mickiene, Aukse
Gomez, Veronica
Turi, Gergo
Souckova, Lenka
Marin, Alexandru
Tolksdorf, Kristin
Nicolay, Nathalie
Rose, Angela M. C.
INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2024, 18 (08)
[5] Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study
Monge, Susana
Humphreys, James
Nicolay, Nathalie
Braeye, Toon
Van Evercooren, Izaak
Hansen, Christian Holm
Emborg, Hanne-Dorthe
Sacco, Chiara
Mateo-Urdiales, Alberto
Castilla, Jesus
Martinez-Baz, Ivan
de Gier, Brechje
Hahne, Susan
Meijerink, Hinta
Kristoffersen, Anja Brathen
Machado, Ausenda
Soares, Patricia
Nardone, Anthony
Bacci, Sabrina
Kissling, Esther
Nunes, Baltazar
INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2024, 18 (04)
[6] Predictors of willingness to receive updated 2023-2024 COVID-19 booster vaccines among a convenience sample in Minnesota
Ricke, I. J.
Spaulding, A. B.
Rajtar, N. N.
Benton, E. M.
Anderson, I. G.
Lundberg, L.
Mussiel, A.
Nguyen, R. H. N.
VACCINE, 2024, 42 (15) : 3499 - 3504
[7] Use of Updated COVID-19 Vaccines 2023-2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2023
Regan, Joanna J.
Moulia, Danielle L.
Link-Gelles, Ruth
Godfrey, Monica
Mak, Josephine
Najdowski, Morgan
Rosenblum, Hannah G.
Shah, Melisa M.
Twentyman, Evelyn
Meyer, Sarah
Peacock, Georgina
Thornburg, Natalie
Havers, Fiona P.
Saydah, Sharon
Brooks, Oliver
Talbot, H. Keipp
Lee, Grace M.
Bell, Beth P.
Mahon, Barbara E.
Daley, Matthew F.
Fleming-Dutra, Katherine E.
Wallace, Megan
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2023, 72 (42): : 1140 - 1146
[8] COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19-Associated Hospitalization Among Residents in Nursing Homes - National Healthcare Safety Network, United States, October 2023-February 2024
Franklin, David
Barbre, Kira
Rowe, Theresa A.
Reses, Hannah E.
Massey, Jason
Meng, Lu
Dollard, Philip
Dubendris, Heather
Stillions, Molly
Robinson, Lindsay
Clerville, Jacques W.
Slifka, Kara Jacobs
Benin, Andrea
Bell, Jeneita M.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2024, 73 (15): : 339 - 344
[9] Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023
Link-Gelles, Ruth
Weber, Zachary A.
Reese, Sarah E.
Payne, Amanda B.
Gaglani, Manjusha
Adams, Katherine
Kharbanda, Anupam B.
Natarajan, Karthik
DeSilva, Malini B.
Dascomb, Kristin
Irving, Stephanie A.
Klein, Nicola P.
Grannis, Shaun J.
Ong, Toan C.
Embi, Peter J.
Dunne, Margaret M.
Dickerson, Monica
McEvoy, Charlene
Arndorfer, Julie
Naleway, Allison L.
Goddard, Kristin
Dixon, Brian E.
Griggs, Eric P.
Hansen, John
Valvi, Nimish
Najdowski, Morgan
Timbol, Julius
Rogerson, Colin
Fireman, Bruce
Fadel, William F.
Patel, Palak
Ray, Caitlin S.
Wiegand, Ryan
Ball, Sarah
Tenforde, Mark W.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2023, 72 (21): : 579 - 588
[10] Use of an Additional Updated 2023-2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024
Panagiotakopoulos, Lakshmi
Godfrey, Monica
Moulia, Danielle L.
Link-Gelles, Ruth
Taylor, Christopher A.
Chatham-Stephens, Kevin
Brooks, Oliver
Daley, Matthew F.
Fleming-Dutra, Katherine E.
Wallace, Megan
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2024, 73 (16): : 377 - 381

← 1 2 3 4 →